Pharmacology ACS Pharmacology & Translational Science
Adenosine Shifts May Blunt Bacterial Defense in Severe COVID-19 and Sepsis
- Patient plasma profiling by LC-MS/MS showed disturbed ATP, AMP and adenosine in severe COVID-19 and sepsis; non-survivors showed a steeper ATP-to-adenosine shift, and adenosine was higher in septic non-survivors.
- Healthy-donor immune cells exposed to severe COVID-19 plasma took on an exhausted T-cell phenotype, and cells exposed to septic ICU plasma cleared E. coli less effectively.
- Adding adenosine weakened bacterial killing, while the A1 antagonist DPCPX alone improved it, pointing to adenosine receptor signaling as a possible therapeutic handle (abstract-level, in vitro).
An A1 antagonist improving killing on its own is the odd result here, and I'd want it explained before anyone calls this a target. DPCPX alone helping implies tonic adenosine tone in the assay, yet plasma adenosine is notoriously unstable ex vivo. Next step: A2A versus A1 selectivity, CD39/CD73 inhibition as a comparator, and a bacterial-burden readout in a septic animal model.
Paper: ACS Pharmacology & Translational Science ↗ Purinergic Imbalance and Adenosinergic Modulation of Antibacterial Activity in Severe COVID-19 and Sepsis